Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1):53-65

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  MIBG IN NEUROBLASTOMA


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1):53-65

Copyright © 2013 EDIZIONI MINERVA MEDICA

lingua: Inglese

131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma

Dubois S. G., Matthay K. K.

Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA


PDF  


Neuroblastoma is an aggressive childhood cancer, with a propensity for early widespread metastasis. Approximately 90% of tumors accumulate the norepinephrine analogue metaiodobenzylguanidine (MIBG) avidly, allowing the use of radiolabeled MIBG for targeted imaging and radiotherapy. After preclinical studies demonstrated activity of 131I-MIBG in models of neuroblastoma, clinical development of this agent ensued. Early clinical trials of 131I-MIBG in patients with relapsed or refractory neuroblastoma defined the toxicity profile of this agent, with myelosuppression as the main dose-limiting toxicity. Subsequent trials defined the activity of 131I-MIBG, with response rates of 20-40% in patients with relapsed or refractory disease. More recent clinical trials have tested 131I-MIBG in combination with chemotherapy or as a component of myeloablative therapies. Given the documented activity of 131I-MIBG, future studies will need to evaluate the impact of radiation sensitizers on this activity and define the role of this agent in treating patients with newly diagnosed high-risk neuroblastoma.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

duboiss@peds.ucsf.edu